Neurochemical and Psychoanalytical Approaches to Mania by Dr J C Cookson and Dr T Silverstone (Maudsley Hospital and Academic Unit of Human Psychopharmacology, St Bartholomew's Hospital, London) There have been two main theoretical approaches towards understanding the pathogenesis of mania, the neurochemical and the psychoanalytical. Although the psychoanalytical approach is perhaps more concerned with the content and meaning of the illness for each individual than is the neurochemical, there are certain similarities between the ways in which both theories account for the observed clinical phenomena. This paper reviews the current neurochemical and psychoanalytic theories in the context of the relevant clinical findings and attempts to draw parallels between the two approaches.
PHARMACOLOGICAL EVIDENCE
(1) Catecholamines Schildkraut (1965) proposed that catecholamine pathways within the brain may be overactive in mania. The amines most studies have been noradrenaline (NA) and dopamine (DA) . Recent studies of the NA and DA metabolites, although somewhat equivocal, tend to add support to this view (Usdin 1977) but at present the main evidence is still pharmacological (Shopsin et al. 1976 ). Many of the drugs that are commonly used and effective in treating mania (e.g. chlorpromazine and haloperidol, APA 1975) are potent antagonists of the actions of catecholamines, particularly dopamine (see Goodman & Gilman 1975) . However, the drugs named are relatively non-specific in their mechanisms of action and it is possible that in the large doses that are often needed to control mania (Royal Society of Medicine 1976) their less potent actions upon other transmitters may be important. Another possible explanation of the need for these high doses arises from the finding that blood levels of chlorpromazine are lower than expected during the treatment of some excited psychotic patients (Rivera-Calimlin et al. 1976 ).
(i) Amphetamines particularly dextro-amphetamine (d-AMP) and methyl-amphetamine (m-AMP) provide a means of studying the role of catecholamines, for in behaviourally effective doses their primary actions appear to increase the release and block the re-uptake of catecholamines, thereby indirectly stimulating postsynaptic receptors for DA and NA (Carlsson 1970) . It has also been found that certain mid-Dr J C Cookson brain dopaminergic neurones are themselves inhibited by low systemic doses of d-AMP, mainly through a neuronal feedback pathway (Bunney & Aghajanian 1977) .
In controlled studies in normal subjects these drugs produce euphoria and whereas low doses are sometimes associated with feelings of calmness, larger ones generally produce nervousness (Martin et al. 1971 ). Some of the euphoriant effects of amphetamines may be related to the release of DA rather than NA, for the DA antagonist pimozide (PMZ) has been found to reduce the euphoriant effect of very large doses of d-AMP in addicts (Johnsson 1972) . A recent study of the effect of small (2 mg) doses of PMZ with d-AMP (10 mg) would support this view. PMZ attenuated the arousal induced by d-AMP (Silverstone & Fincham 1978) .
There are few reports on the responses of manic patients to amphetamines and the findings are of two types. Firstly, when amphetamines are given to bipolar depressed patients, a proportion of them become hypomanic or manic (Gerner et al. 1976 , Van Kammen & Murphy 1975 and intravenous m-AMP makes some manic patients worse (S. Checkley, personal communication). This seems to support the view that overactivity of catecholamine pathways can lead to and may underlie mania. On the other hand, there is a report that d-AMP (30 or 50 mg by i.v. infusion over 30 min) given in an open study to 6 manic patients led to sedation and a reduction in manic symptomatology lasting 1-3 h in all cases (Beckman & Heinemann 1976) . (ii) L-dihydroxyphenylalanine (1-dopa) given in large oral doses (3 g/day), while ineffective as an antidepressant, does produce psychomotor activa-agonists and amphetamines may indicate that an as yet unknown behaviourally inhibitory catecholamine pathway is underactive in mania.
(v) DA-agonists. Of the neuroleptics, PMZ is one of the most specific in its DA-receptor blocking activity having little, if any, NA receptor blocking action (Anden et al. 1970) . We have studied the effect of pimozide (8, 6, and 4 mg over 3 successive days) upon 5 manic patients using a modification of the Manic State Rating Scale devised by Beigel et al. (1971) . We found that all 5 patients improved over the whole range of symptoms rated and this improvement was not associated with sedation (Cookson & Silverstone 1976) . Similarly, the manic patient described by Gerner et al. (1976) improved on pimozide (14 mg/day).
Our subsequent experience with PMZ has been that with doses up to 24 mg/day a proportion of patients are controlled. However, in many of its effects PMZ has been reported to be less potent than haloperidol by a factor of about 2-3 (Pinder et al. 1976) and we do not know whether the remaining patients would be controlled by higher doses of PMZ. Firm recommendations regarding the place of PMZ in the management of mania must await the outcome of a doubleblind trial which we and others are undertaking.
(vi) NA-antagonists Central NA receptors are only beginning to be characterized pharmacologically (Bloqm 1975) and the role of NA in mania has been comparatively little studied. Clozapine, which seems to be a relatively selective NAantagonist in biochemical tests, is reported to be an effective sedative in severe psychotic agitation (Van Prang et al. 1976 ). Its effects in mania will be of interest.
(2) 5-Hydroxytryptamine (Serotonin, 5-HT) One of the findings used by Mendels & Frazer (1975) in support of the view that central serotonergic activity is reduced in mania (as well as in some cases of depression)-is that in some animal species the drug p-chlorophenylalanine, which inhibits the synthesis of 5HT, leads to a behavioural syndrome with some features resembling mania (insomnia, hyperactivity, hyperphagia and increased sexual activity).
Levels of 5-hydroxyindole acetic acid (5HIAA) in the lumbar CSF are increased when patients simulate the motor activity of mania (Post et al. 1973 ). However, 5HIAA levels in true mania, using the probenecid technique, are reported to be lower than normal in some patients (Goodwin & Post 1974) but this is not firmly established. Such findings would support the idea that central 5HT turnover is reduced in mania and pharmacological evidence is also consistent with this idea.
tion. It can also exacerbate pre-existing symptoms in both depressive psychosis and schizophrenia. When given to depressed patients with a history of mania it has been reported to produce typical hypomanic or manic symptoms (Bunney et al. 1972 , Frazer & Mendels 1977 . These findings also may mean that activation of catecholamine pathways can lead to mania, but it should be remembered that 1-dopa can interfere with the metabolism of 5HT (Graham-Smith 1976) as well as DA and NA (Boakes etal. 1975 ).
(iii) Inhibitors of Synthesis of Catecholamines. Alpha-methylparatyrosine (AMPT) inhibits tyrosine hydroxylase and thereby leads to reduction in levels of catecholamines in the brain (Spector et al. 1965) . In man it produces fatigue, dysphoria and sedation (Ahlenius et al. 1973) . Given to 7 manic patients it was reported to produce improvement in 5 and deterioration in 1. Sedation was a feature of its action in some patients and 3 patients showed a small fall in blood pressure (Brodie et al. 1971) . In contrast to these findings, an anti-manic effect was not observed with AMPT by Shopsin et aL (1976) .
Fusaric acid inhibits dopamine-fi-hydroxylase (DBM) in noradrenergic cells and thereby leads to depletion of stores of NA in these cells. This raises the possibility that DA may become a false transmitter at these sites. When given to 8 manic patients it led to deterioration in the severe cases although there appeared to be some improvement in those with mild symptoms (Sack & Goodwin 1974) .
There is little evidence that noradrenergic transmission was significantly reduced by fusaric acid in these patients. Indeed, for the group as a whole, there was no change in total sleep time and there was minimal effect on blood pressure.
It is difficult to draw any firm conclusions given these somewhat inconsistent findings.
(iv) Piribedil, apomorphine and bromocriptine are thought to stimulate DA receptors directly. Gerner et al. (1976) described one bipolar depressed patient in whom a large dose of piribidel (200 mg/day) led to a manic episode. In contrast there are reports that low doses of piribedil or apomorphine have slight anti-manic effects in some patients in open studies (Arbuthnott & Murray 1976 , Post et al. 1976 , Corsini et al. 1977 . At first sight this seems contrary to the idea that DA pathways are overactive in mania, but several possible explanations have been proposed, in terms, for example, of autoreceptors which inhibit the firing of DA cells (Carlsson 1977) or of inhibitory and excitatory types of DA receptors (Cools 1977) . It does seem possible that the anti-manic action of both DA-S3chizophrenia (i) Monoamine re-uptake inhibitors. There appear to have been no controlled trials of these drugs in mania, but in uncontrolled trials imipramine has been reported to have anti-manic effects (Van der Velde & Gordon 1973 , Mendels & Frazer 1975 . However, as this drug affects catecholamines as well as 5HT it is uncertain how it exerts whatever anti-manic effect it may have.
(ii) 5HT-precursors. There are two reports on the use of large oral doses of y-tryptophan (L-TP) in mania. Prange et al. (1974) in a small controlled study found L-TP slightly more effective than a small dose of chlorpromazine. Murphy et al. found that L-TP reduced manic symptoms in some patients. Sedation was part of the action, but a few patients showed a complete remission of symptoms.
On the other hand, there is a report (Van Woert et al. 1977 ) on the use of 5-hydroxytryptophan in combination with carbidopa in myoclonus, in which 10 out of 18 patients showed some mental stimulation, including euphoria and hvpomania.
(iii) Methysergide (MSG) is an antagonist of some of the peripheral actions of 5HT. There is as yet little evidence of its ability to antagonize the effects of 5HT within the mammalian brain (Aghajanian et al. 1975 ). On the basis of earlier experiments on the avian brain, Dewhurst (1968) suggested that MSG might be effective in the treatment of mania. While the results of uncontrolled trials appeared at first to support this hypothesis, subsequent controlled trials failed to confirm that MSG had any anti-manic activity. In fact, it exacerbated the symptoms in some patients (Coppen et al. 1969 , Court & Mai 1970 .
(iv) Fenfluramine (FF) is an anorectic drug with sedative side-effects that acts in part by release of 5HT in the CNS (Garattini & Samanin 1976) . Pearce (1973) found some improvement in 4 manic patients with doses up to 180 mg/day. We confirmed this finding in 7 manic patients. Sedation was a prominent effect in all cases, but other symptoms of mania were less affected (Cookson & Silverstone 1976) .
It would therefore seem that drugs such as L-TP and FF, which activate 5HT pathways, ameliorate at least the motor symptoms and insomnia of mania while drugs such as MSG, which block 5HT neurotransmission, exacerbate the condition. This might imply that certain 5HT pathways are underactive in mania. It is uncertain whether such underactivity is primary or secondary and it must be borne in mind that both FF (Garattini & Samanin 1976) and L-TP (Everett 1974) can also affect the metabolism of catecholamines.
(3) Acetylcholine (ACh) Janowski et al. (1972) presented evidence that ACh has an important role in affective illness. Thus, atropinic drugs produce euphoria and anti-cholinesterases produce dysphoria and anergy. There are also toxic-confusional effects with both groups of drugs. These authors reported that i.v. injection of the cholinesterase inhibitor physostigmine produced transient reduction in the severity of mania in 8 patients. However they provided few details of the mental state of the patients. Carrol et al. (1973) gave physostigmine to 2 manic patients and found marked psychomotor inhibition and reduced aggression, but the patients remained grandiose and elated with flight of ideas.
The mechanisms whereby cholinesterase inhibitors exert their effects are very difficult to disentangle (Cookson & Paton 1969) . One possible explanation of those findings is that certain ACh pathways are underactive in mania and can be potentiated by physostigmine. ACh is very widely distributed in the brain and is probably involved in most aspects of behaviour (De Feudis 1974) . The receptors involved in the actions of physostigmine in mania have yet to be characterized pharmacologically. Davies et al. found evidence that they might be muscarinic and this raises the question of whether atropinic drugs make mania worse when given to counteract the side-effects of neuroleptic drugs upon the extrapyramidal system.
PSYCHOANALYTICAL THEORIES
The following account is based on the writings of Freud (1917, 1921) , Abraham (1911 Abraham ( , 1924 , Winicott (1935) , Klein (1935) and Lewin (1951) .
Freud thought that recent psychological factors were important as precipitants of some manic episodes, although in other cases mania seemed to develop with an endogenous rhythm. Psychological factors in childhood are thought to have a role in predisposing the adult to mania. The role of life events has not however been the subject of a controlled study. Freud wrote of the unsolved 'economic problem' of mania and by this he included what is now known to be the important genetic (and probably neuro-chemical) contribution (Allen 1976 ) to its aetiology. Freud saw the psychological aspect as the loss of an ambivalently regarded 'object' which would be experienced with depressive anxiety and guilt. This was similar to his view on the origin of depression and he said that mania and depression seemed to be dealing with the same intraphysic situation. Our understanding of this was enlarged by Winnicott and Klein who introduced the idea of the 'manic defence' against depressive anxiety. These authors viewed mania and depression as not simply opposites but as pathological developments of two alternative ways of dealing with the same anxiety, the depressive position and the manic defence. The latter is seen as protecting the ego against despair, but interrupting the reparation that seems obligatory and is undertaken in the depressive position. However, a manic form of reparation can occur and some of the identifications made in mania can be seen as potential advances in individual development.
In psychoanalytical theory, depressive anxiety and the manic defence first arise in early life when oral activities predominate and the mechanisms underlying mania reflect this. Astute clinical observations led Abraham (1924) to regard the basis of all manic symptoms as increased oral drives with accompanying fantasies of cannibalistic incorporation. Manic patients seem to identify with what is being 'devoured', including both parents in the primal scene conceived orally and therefore phallic identification is a central feature of mania. The increased motor activity in mania was attributed to 'muscle eroticism', a diversion channel for surplus libido.
Lewin traced the origin of elated moods to the contentment experienced at the breast when what he called the 'oral triad' of wishesto eat, to be eaten (or 'taken in') and to sleepare satisfied. In mania the wish to be 'taken in' is offset by a dread of phallic rivalry and oral devouring activity is prolonged and the wish to sleep postponed. However, the latter finds expression in the occurrence during mania of some of the mental processes normally found in dreams, such as omnipotence, denial and flight of ideas. Kubie (1948) stated that psychological processes can occur only when there is a time lag between a tissue need and its alleviation.
To account for the changes in oral activity that occur when a normal adult becomes manic Abraham spoke of 'regression' to an early ('oral') stage of libidinal development.
In the view of Melanie Klein, the manic defence and mania can be thought of as including a vicious circle. - The depressive anxieties that would arise from the real or fantasied destruction of the loved object are countered by manic defences (omnipotent control, triumph and contempt) which lead to further attacks upon the object and tend, therefore, to intensify the anxiety. It is tempting to see this in terms of a neuronal loop with positive feedback and this may help to explain the lability of symptoms in mania and why such large doses of medication are sometimes needed to relieve them.
Psychoanalytical theory makes an association between disturbances of mood and aggression. Abraham (1911) stated that in mania both positive and negative libido escape repression. This statement reflects the difficult evolution of the psychoanalytic 'drive theory' (Bibring 1936) . It implies that mania also involves disturbances in the mechanisms underlying aggression. CONCLUSION Can the psychoanalytical viewpoint be related to the psychopharmacological evidence? The idea that mania and depression are not simply opposites but have some similarities is! shared in some neuropharmacological theories. Mendels and Frazer (1975) argued that both may be associated with similar abnormalities in central serotonergic pathways. The connection made by psychoanalysts between oral behaviour and mood and sleep has pharmacological counterparts. For instance, amphetamines have effects on mood, arousal and appetite in normal subjects (see Silverstone 1976) . We suggest that the findings from behavioural pharmacology in animals might provide a link between the two approaches.
The psychoanalytical concept of increased oral drives may correspond to the psychopharmacological finding of increased catecholamine activity. On the basis of electrical self-stimulation experiments in animals (Crow 1972) it appears that the mesolimbic DA pathway and the dorsal NA pathway are concerned with drive or motivation and reinforcement. The mesolimbic DA pathway is also important in locomotor activity (Kelly etal. 1975) .
A similar parallel might be drawn between the psychoanalytical concept of prolonged oral devouring, together with postponement of sleep and the pharmacological evidence of underactivity of ACh and 5HT pathways in mania. There is evidence that ACh (Domino & Olds 1968) and 5HT (Wise et al. 1973) are involved in behavioural inhibition and avoidance learning and that 5HT is involved in satiety (Blundell et al. 1976 ) and in slow wave sleep (Jouvet & Pujol 1974) . Catecholamine pathways, on the other hand, are important in arousal (Boakes etal. 1975) .
The primary steps that bring about the changes in the organization of drives in mania that psychoanalysts call regression remain to be accounted for neurochemically. This will require both further pharmacological research into the neurochemical basis of arousal, sleep, aggression and such drive-orientated behaviour as feeding and sexual activity and classification of the functions of identification and other mechanisms that underly it. There is also a need for reliable information based on well-controlled studies of the clinical effects of specific drugs upon the symptoms and course of mania.
DISCUSSION
Professor S Hirsch (London) suggested that the concept of increased devouring did not add to an understanding of the problem. The analyst was simply describing the behaviour which he saw. Instead of devouring, one could talk of increased appetite, but the description had no predictive value and did not lead to a hypothesis which helped to elucidate the problem. Dr Cookson said that he had been attempting to draw parallels between the two approaches. The psychoanalyst was more concerned with the meaning of the illness to the individual patient.
Dr M S Hussain (Canterbury) said that they were concerned with both recurrence and periodicity of the illness and he felt that neither the psychopharmacological nor the psychoanalytic model explained them.
At a more practical level, he said there had been recent reports about brain damage caused by haloperidol and lithium taken together in high doses. He asked if there was any evidence of pimozide and lithium carbonate being used together to control manic-depressive psychosis. If so, was it safe or had it caused brain damage? Dr Cookson said that the only report he knew of in which pimozide had been used in mania was that of Gerner and his colleagues (1976) in the American Journal ofPsychiatry. Here lithium was used only after pimozide and he himself had not used the two together.
Dr M A Ezzat (Lincoln) said that the modem trend was to implicate dopamine in depression. With schizoaffective patients, once the depression was improved florid symptoms of psychosis increased, which would be consistent with an increase in dopamine. The depression would be lifted and the psychotic features would be more apparent, but this had not been Dr Crow's experience. Dr Crow said that he too was surprised by the results. If they were genuine they implied that one should be treating schizoaffective patients with lithium and not with neuroleptics. However, his earlier response to Dr Robin still stood. The patient numbers were small, but the response was much less than in patients who did not have affective disorders.
Dr I C Church (North Humberside) asked if biochemical studies gave any clues to the tempo swings from mania to depression. These varied considerably and were perhaps not consistent from one patient to another. Dr Cookson felt that so far the pharmacological evidence contributed little to our knowledge of these swings, although if more were known about the mechanism of action of lithium it might.
Dr Iversen (Chairman) agreed that the biochemical evidence so far gave no answer whatever.
Dr G Silverman (Southall) asked speakers to comment on the possibility that the etiology of schizophrenia might depend on an inherited, unstable brain circuit which, in some instances, it might be possible to correct.
Dr Crow said that one problem was the enormous heterogeneity among groups of schizophrenic patients. They were not very good at describing the variables that differentiated one patient from another. Certainly there were patients who had a genetically determined susceptibility, but there were others in whom the illness came on at a particular time and seemed to progress from there. For them, the explanation would not seem to apply. The difficulty was to define sub-groups, a clinical problem that had existed for a long time. When the sub-groups had been defined it might be appropriate to look at them biochemically. Dr Iversen (Chairman) felt that Dr Silverman's suggestion was perfectly plausible. On the other hand, it was equally possible that there was a biochemical etiology for schizophrenia involving chemical mechanisms in the brain that were as yet unknown. Some years ago, the only known brain transmitter was acetylcholine. Now 8-10 monoamine and amino acid transmitters were known to exist and within the last 12-18 months another 8-10 peptide transmitters had begun to emerge. It was perfectly possible that a biochemical abnormality existed in some hitherto unidentified system.
